news
News & Events
-
May 30, 2024 -
events
January 16, 2024 PepTalk: Developability of Bispecific Antibodies
Read more
-
news
November 29, 2023 Almac Discovery and Queen’s University launch state-of-the-art Chemoproteomics facility in Belfast
Read more
-
events
September 28, 2023 Cancer Cachexia Society Conference
Read more
-
events
July 14, 2023 RSC Organic Chemistry Ireland Meeting 2023
Read more
-
news
June 6, 2023 WEE1 Inhibitor discovered by Almac Discovery advanced into two clinical studies addressing the treatment of advanced solid tumoursÂ
Read more
-
news
August 24, 2022 Almac Discovered Molecule Progresses into Clinical Development with its strategic licensee Vaderis Therapeutics AG
Read more
-
news
June 1, 2022 Almac Discovery nominates a first candidate molecule from its Protein Drug Conjugate (PDC) Platform to progress into pre-clinical development
Read more
-
news
May 20, 2022 Almac Discovery and HitGen Announce Strategic Research Collaboration
Read more
-
news
December 16, 2021 Debiopharm Further Explores the Potential of Potent, Highly Selective WEE1 Inhibitor in Phase 1 Cancer Study
Read more
-
news
July 20, 2021 Almac Discovery Expands Disease Focus into Respiratory Disease
Read more
-
news
May 18, 2021 Almac Discovery Publishes Ground-breaking Cancer Research
Read more
-
news
January 18, 2021 Professor Daniel Longley Joins Almac Discovery to Accelerate Colorectal Cancer Research
Read more
-
news
June 18, 2020 Almac Discovery to Present Updates on Key Oncology Programmes at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
Read more
-
news
May 14, 2020 Almac Discovery Enters Into Licensing Agreement for the Development & Commercialisation of ALM301
Read more
-
news
April 29, 2020 Almac Discovery to Collaborate with MSD on selected DUB therapeutic targets
Read more
-
news
March 5, 2020 Debiopharm Advances its Potent Wee1 Inhibitor into Clinical Phase
Read more
-
news
October 1, 2019 Almac Group Appoints Dr Alan Lamont as VP BD & Licensing
Read more
-
news
March 20, 2019 Almac Discovery and Elasmogen to Share Anti-ROR-1 VNAR Data at American Association of Cancer Annual Meeting
Read more
-
news
March 18, 2019 Almac Discovery Showcases its Deubiquitinase Drug Discovery Expertise at the American Association of Cancer Research Annual Meeting in Atlanta
Read more
-
news
August 6, 2018 VNAR Based Oncology Platform in development
Read more
-
news
July 5, 2018 Dr. Xavier Jacq Appointed Vice President, Biology
Read more
-
news
April 23, 2018 Latest developments in DUB inhibitors shared at Proteasome & Autophagy Congress
Read more
-
news
April 10, 2018 Almac Discovery to Present at AACR 2018
Read more
-
news
January 29, 2018 Research Highlighted in Nature Chemical Biology
Read more
-
news
December 4, 2017 USP7 inhibitors from UbiPlexTM Platform published
Read more
-
news
September 4, 2017 ALM201 Poster Presentation at 2017 ESMO Congress
Read more
-
news
July 3, 2017 ALM201 – Orphan Drug Designation Granted in Ovarian Cancer
Read more
-
news
June 20, 2017 Agreement with Debiopharm to Develop Novel Wee-1 Inhibitor
Read more
-
news
May 8, 2017 Wee-1 kinase patent approval granted
Read more
-
news
February 14, 2017 Therapy-resistant cancer tumours targeted with RCSI
Read more
-
news
May 30, 2016 Diseases of the eye explored with McClay Foundation and UU
Read more
-
news
October 5, 2015 European Patent Protection for ALM201 Secured
Read more
-
news
July 10, 2015 Ubiquitin Specific Protease Collaboration with Genentech
Read more
-
news
September 4, 2013 ÂŁ13m Investment Cancer Research Initiatives with QUB
Read more
-
news
April 27, 2009 Minister Praises Craigavon Life Sciences Firm’s Commitment to R&D
Read more
-
news
June 10, 2008 Almac Group Launches Oncology Discovery Arm
Read more